Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) was the recipient of a significant decline in short interest in August. As of August 15th, there was short interest totalling 97,900 shares, a decline of 6.6% from the July 31st total of 104,800 shares. Based on an average daily volume of 26,300 shares, the short-interest ratio is presently 3.7 days. Currently, 3.2% of the company’s stock are short sold.
Hedge Funds Weigh In On Eterna Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. CI Private Wealth LLC acquired a new position in shares of Eterna Therapeutics during the fourth quarter worth $197,000. Sippican Capital Advisors grew its stake in shares of Eterna Therapeutics by 60.0% during the second quarter. Sippican Capital Advisors now owns 21,601 shares of the company’s stock worth $49,000 after purchasing an additional 8,101 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Eterna Therapeutics during the fourth quarter worth $56,000. Geode Capital Management LLC acquired a new position in shares of Eterna Therapeutics during the fourth quarter worth $45,000. Finally, Goldman Sachs Group Inc. acquired a new position in Eterna Therapeutics in the second quarter valued at $26,000. Institutional investors and hedge funds own 6.04% of the company’s stock.
Eterna Therapeutics Trading Down 6.6 %
Shares of ERNA stock opened at $2.28 on Friday. The firm has a fifty day moving average price of $2.54 and a 200 day moving average price of $2.86. The company has a market cap of $12.33 million, a P/E ratio of -0.40 and a beta of 4.23. Eterna Therapeutics has a 12 month low of $1.90 and a 12 month high of $8.52.
Eterna Therapeutics Company Profile
Eterna Therapeutics Inc, a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.
- Five stocks we like better than Eterna Therapeutics
- How to Find Cloud Software Company Stocks to Trade and Invest
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Invest in Artificial Intelligence
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
- 3 Monster Growth Stocks to Buy Now
- 5 Critical Takeaways From MongoDB’s Q2 Results for AI Investors
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.